

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JC17 Rec'd PCT/PTO 30 MAR 2005

ATTY. DCK
TX/4-32662A
APPLICATION NO.

Sheet 1 of 1

10/529776

APPLICANT
ALBERT ET AL.
FILING DATE

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
DP	AM	00/66559	11/9/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	02/081449	10/17/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	03/020716	3/13/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DP	AR	Palani et al., "Discovery of 4-[(Z)-(4-Bromophenyl)-(ethoxyimino)methyl]-1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl-1,4'-bipiperidine N-Oxide (SCH 351125): An Orally Bioavailable Human CCR5 Antagonist for the treatment of HIV Infection", J. Med. Chem., Vol. 44, No. 21, pp. 3339-3342 (2001).
	AS	
	AT	

EXAMINER

Sarah Pedinger

DATE CONSIDERED

05/04/06

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.